MA30142B1 - Agonistes du recepteur de neuropeptide-2 - Google Patents

Agonistes du recepteur de neuropeptide-2

Info

Publication number
MA30142B1
MA30142B1 MA31085A MA31085A MA30142B1 MA 30142 B1 MA30142 B1 MA 30142B1 MA 31085 A MA31085 A MA 31085A MA 31085 A MA31085 A MA 31085A MA 30142 B1 MA30142 B1 MA 30142B1
Authority
MA
Morocco
Prior art keywords
neuropeptide
receptor agonists
obesity
diabetes
moieties
Prior art date
Application number
MA31085A
Other languages
English (en)
Inventor
Karin Conde-Knape
Waleed Danho
George Ehrlich
Nader Fotouhi
David C Fry
Wajiha Khan
Anish Konkar
Cristina Martha Rondinone
Joseph Swistok
Rebecca Anne Taub
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30142(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30142B1 publication Critical patent/MA30142B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Agonistes du récepteur de neuropeptide-2 Il est proposé dans le présent mémoire des agonistes du récepteur de neuropeptide-2, de formule (I), Y¿ I Y-R1-R2-X-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-NH2 (I) ainsi que leurs sels, dérivés et fragments pharmaceutiquement acceptables, formule dans laquelle les substituants sont ceux décrits dans le présent mémoire. Ces composés, et les compositions pharmaceutiques les contenant, sont utiles pour le traitement de maladies telles que, par exemple, l'obésité et le diabète.
MA31085A 2005-12-07 2008-07-01 Agonistes du recepteur de neuropeptide-2 MA30142B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74807105P 2005-12-07 2005-12-07
US85524906P 2006-10-30 2006-10-30

Publications (1)

Publication Number Publication Date
MA30142B1 true MA30142B1 (fr) 2009-01-02

Family

ID=37964711

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31085A MA30142B1 (fr) 2005-12-07 2008-07-01 Agonistes du recepteur de neuropeptide-2

Country Status (18)

Country Link
US (2) US7642244B2 (fr)
EP (1) EP1962959B1 (fr)
JP (1) JP5000663B2 (fr)
KR (1) KR101059602B1 (fr)
AR (1) AR057222A1 (fr)
AT (1) ATE549350T1 (fr)
AU (1) AU2006324076A1 (fr)
BR (1) BRPI0619573A2 (fr)
CA (1) CA2630649A1 (fr)
EC (1) ECSP088511A (fr)
ES (1) ES2381497T3 (fr)
IL (1) IL191636A (fr)
MA (1) MA30142B1 (fr)
NO (1) NO20082445L (fr)
NZ (1) NZ568772A (fr)
RU (2) RU2430108C2 (fr)
TW (1) TWI321474B (fr)
WO (1) WO2007065808A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010069242A (ko) * 2000-09-05 2001-07-25 양우용 저주파 물리치료 겸용 혈압 강하기
CA2630649A1 (fr) * 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Agonistes du recepteur du neuropeptide-2
US8299023B2 (en) * 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
CN102202681A (zh) * 2008-11-05 2011-09-28 霍夫曼-拉罗奇有限公司 神经肽-2受体(y-2r)激动剂及其用途
US9260500B2 (en) 2009-07-02 2016-02-16 Takeda Pharmaceutical Company Limited Peptide and use thereof
WO2011033068A1 (fr) * 2009-09-18 2011-03-24 Novo Nordisk A/S Agonistes du récepteur y2 à action prolongée
JP2013507414A (ja) * 2009-10-13 2013-03-04 エフ．ホフマン−ラ ロシュ アーゲー 神経ペプチド−２受容体（ｙ−２ｒ）アゴニスト
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
CA2822481A1 (fr) * 2011-01-03 2012-07-12 F. Hoffmann-La Roche Ag Composition pharmaceutique a base d'un complexe associant un anticorps anti-dig et de la digoxigenine conjuguee a un peptide
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
EP2870180B1 (fr) 2012-07-04 2024-08-28 F. Hoffmann-La Roche AG Anticorps anti-biotine et procédés d'utilisation
DK2869837T3 (en) 2012-07-04 2016-09-26 Hoffmann La Roche Anti-theophylline antibodies and methods of use
RU2684595C2 (ru) 2012-07-04 2019-04-09 Ф.Хоффманн-Ля Рош Аг Ковалентно связанные конъюгаты антиген-антитело
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
CN105722526B (zh) 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
EP3068795B1 (fr) 2013-11-15 2019-03-06 Novo Nordisk A/S Beta-homo arginine substitution au position 35 de hpyy(1-36)
EP3089758B1 (fr) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Conjugués d'anticorps helicar-anti-helicar liés par covalence et leurs utilisations
CN105899540B (zh) 2014-01-03 2020-02-07 豪夫迈·罗氏有限公司 双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及它们作为血脑屏障穿梭物的应用
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
TWI694082B (zh) 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
CR20220206A (es) 2019-11-11 2022-06-16 Boehringer Ingelheim Int Agonistas del receptor npy2
JP7661478B2 (ja) 2020-08-07 2025-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性ｎｐｙ２受容体アゴニスト

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
KR960701653A (ko) * 1993-03-29 1996-03-28 발라수브라마니암 엠비카이파칸 펩타이드 yy의 유사체 및 그의 용도
AUPO029096A0 (en) 1996-06-05 1996-07-04 Crc For Biopharmaceutical Research Pty Ltd Npy y2 agonists
US6013633A (en) 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
WO2001009120A1 (fr) * 1999-07-28 2001-02-08 Ortho-Mcneil Pharmaceutical, Inc. Derives d'amines et d'amides utilises en tant que ligands pour le recepteur y5 du neuropeptide y, utile dans le traitement de l'obesite et d'autres troubles
WO2004066966A2 (fr) * 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues du peptide yy
PL1620118T3 (pl) 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
WO2005053726A1 (fr) 2003-11-25 2005-06-16 Bayer Pharmaceuticals Corporation Agonistes selectifs du recepteur de neuropeptide y2
EP1718671A2 (fr) 2004-02-23 2006-11-08 Rheoscience A/S Analogues du peptide yy
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2006091505A2 (fr) 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Agonistes du recepteur y de neuropeptide
CA2630649A1 (fr) * 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Agonistes du recepteur du neuropeptide-2
WO2007085887A1 (fr) 2006-01-27 2007-08-02 Pfizer Products Inc. Agonistes du pyy et leurs utilisations

Also Published As

Publication number Publication date
JP5000663B2 (ja) 2012-08-15
ES2381497T3 (es) 2012-05-28
EP1962959A2 (fr) 2008-09-03
US20070135351A1 (en) 2007-06-14
EP1962959B1 (fr) 2012-03-14
AR057222A1 (es) 2007-11-21
RU2011105310A (ru) 2012-08-20
WO2007065808A2 (fr) 2007-06-14
CA2630649A1 (fr) 2007-06-14
KR20080082672A (ko) 2008-09-11
NZ568772A (en) 2010-05-28
US20100137223A1 (en) 2010-06-03
TW200806311A (en) 2008-02-01
AU2006324076A1 (en) 2007-06-14
IL191636A0 (en) 2008-12-29
RU2430108C2 (ru) 2011-09-27
US8268784B2 (en) 2012-09-18
ATE549350T1 (de) 2012-03-15
ECSP088511A (es) 2008-07-30
BRPI0619573A2 (pt) 2011-10-04
WO2007065808A3 (fr) 2007-08-02
IL191636A (en) 2012-10-31
NO20082445L (no) 2008-09-03
RU2008127265A (ru) 2010-01-20
KR101059602B1 (ko) 2011-08-25
JP2009518349A (ja) 2009-05-07
TWI321474B (en) 2010-03-11
US7642244B2 (en) 2010-01-05

Similar Documents

Publication Publication Date Title
MA30142B1 (fr) Agonistes du recepteur de neuropeptide-2
MA30344B1 (fr) Pyrazoles actifs sur la 11-beta-hsd-1
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MA29731B1 (fr) Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
Barbey et al. Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
MA29926B1 (fr) Derives de pyrazine
MA28747B1 (fr) Dérivés de pyridine
MA31979B1 (fr) (cyclopropylphenyl) phenyloxamides, leur procede de production et leur utilisation comme medicament
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA31754B1 (fr) Cis-imidazolines chirales
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
TN2009000450A1 (fr) Derives de pyridine
MA31766B1 (fr) Composés organiques
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA29909B1 (fr) Derives de pyridazine
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a